Skip to main content
Top
Published in: Archives of Gynecology and Obstetrics 1/2023

21-01-2023 | Surgery | Gynecologic Oncology

Comparison end-to-end anastomosis with ostomy after secondary surgical cytoreduction for recurrent high-grade serous ovarian cancer: observational single-center study

Authors: Luka Matak, Mislav Mikuš, Mario Ćorić, Giulia Spagnol, Magdalena Matak, Goran Vujić

Published in: Archives of Gynecology and Obstetrics | Issue 1/2023

Login to get access

Abstract

We conducted an observational single-center cohort study on patients with recurrent high-grade serous ovarian carcinoma that underwent secondary surgical cytoreduction with extent of partial ileectomy and/or colectomy, followed by adjuvant chemotherapy (Paclitaxel-Carboplatin). All patients performed previously primary debulking surgery without residual disease, followed by three cycles of adjuvant chemotherapy. The aim of this study was to compare survival in patients with ostomy or end-to-end anastomosis that underwent secondary cytoreduction. Furthermore, we investigated the morbidity, the rate, timing and complications of the ostomy or end-to-end anastomosis after secondary cyto-reduction.
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424CrossRefPubMed Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424CrossRefPubMed
2.
go back to reference Katić K, Matković V, Lešin et al (2019) First-line treatment of ovarian cancer FIGO stages IIIB-IV: focus on therapy with bevacizumab—our experience. Libri Oncol 47(2–3):64–70 Katić K, Matković V, Lešin et al (2019) First-line treatment of ovarian cancer FIGO stages IIIB-IV: focus on therapy with bevacizumab—our experience. Libri Oncol 47(2–3):64–70
3.
go back to reference Berek JS, Kehoe ST, Kumar L, Friedlander M (2018) Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynecol Obstet 143:59–78CrossRef Berek JS, Kehoe ST, Kumar L, Friedlander M (2018) Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynecol Obstet 143:59–78CrossRef
4.
go back to reference Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope RC, Wilson TO et al (2006) Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 107:77–85CrossRefPubMed Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope RC, Wilson TO et al (2006) Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 107:77–85CrossRefPubMed
5.
go back to reference Chang SJ, Hodeib M, Chang J, Bristow RE (2013) Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol 130:493–498CrossRefPubMed Chang SJ, Hodeib M, Chang J, Bristow RE (2013) Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol 130:493–498CrossRefPubMed
6.
go back to reference Tseng JH et al (2016) Diverting ileostomy during primary debulking surgery for ovarian cancer: associated factors and postoperative outcomes. Gynecol Oncol 142(2):217–224CrossRefPubMedPubMedCentral Tseng JH et al (2016) Diverting ileostomy during primary debulking surgery for ovarian cancer: associated factors and postoperative outcomes. Gynecol Oncol 142(2):217–224CrossRefPubMedPubMedCentral
7.
go back to reference Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Monts FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248–1259CrossRefPubMed Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Monts FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248–1259CrossRefPubMed
8.
go back to reference Tozzi R et al (2018) Morbidity and reversal rate of ileostomy after bowel resection during visceral-peritoneal debulking (VPD) in patients with stage IIIC-IV ovarian cancer. Gynecol Oncol 148(1):74–78CrossRefPubMed Tozzi R et al (2018) Morbidity and reversal rate of ileostomy after bowel resection during visceral-peritoneal debulking (VPD) in patients with stage IIIC-IV ovarian cancer. Gynecol Oncol 148(1):74–78CrossRefPubMed
9.
go back to reference Kim M, Suh DH, Park JY et al (2018) Survival impact of low anterior resection in patients with epithelial ovarian cancer grossly confined to the pelvic cavity: a Korean multicenter study. J Gynecol Oncol 29(4):e60CrossRefPubMedPubMedCentral Kim M, Suh DH, Park JY et al (2018) Survival impact of low anterior resection in patients with epithelial ovarian cancer grossly confined to the pelvic cavity: a Korean multicenter study. J Gynecol Oncol 29(4):e60CrossRefPubMedPubMedCentral
10.
go back to reference Dood RL, Zhao Y, Armbruster SD et al (2018) Defining survivorship trajectories across patients with solid tumors: an evidence-based approach. JAMA Oncol 4:1519–1526CrossRefPubMed Dood RL, Zhao Y, Armbruster SD et al (2018) Defining survivorship trajectories across patients with solid tumors: an evidence-based approach. JAMA Oncol 4:1519–1526CrossRefPubMed
11.
go back to reference Bommert M, Harter P, Heitz F, du Bois A (2018) When should surgery be used for recurrent ovarian carcinoma? Clin Oncol (R Coll Radiol) 30:493–497CrossRefPubMed Bommert M, Harter P, Heitz F, du Bois A (2018) When should surgery be used for recurrent ovarian carcinoma? Clin Oncol (R Coll Radiol) 30:493–497CrossRefPubMed
13.
go back to reference Du Bois A, Vergote I, Ferron G et al (2017) Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. J Clin Oncol 35:5501 (abstract)CrossRef Du Bois A, Vergote I, Ferron G et al (2017) Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. J Clin Oncol 35:5501 (abstract)CrossRef
15.
go back to reference Harter P, Heitz F, du Bois A (2012) Surgery for relapsed ovarian cancer: when should it be offered? Curr Oncol Rep 14(6):539–543CrossRefPubMed Harter P, Heitz F, du Bois A (2012) Surgery for relapsed ovarian cancer: when should it be offered? Curr Oncol Rep 14(6):539–543CrossRefPubMed
16.
go back to reference National Comprehensive Cancer Network (NCCN) Clinical practice guidelines in ovarian cancer. Version 1.2017 National Comprehensive Cancer Network (NCCN) Clinical practice guidelines in ovarian cancer. Version 1.2017
17.
go back to reference Petrillo M, Fagotti A, Ferrandina G et al (2013) Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors. Gynecol Oncol 131(1):36–41CrossRefPubMed Petrillo M, Fagotti A, Ferrandina G et al (2013) Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors. Gynecol Oncol 131(1):36–41CrossRefPubMed
18.
go back to reference Petrillo M, Ferrandina G, Fagotti A et al (2013) Timing and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapy. Ann Surg Oncol 20(12):3955–3960CrossRefPubMed Petrillo M, Ferrandina G, Fagotti A et al (2013) Timing and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapy. Ann Surg Oncol 20(12):3955–3960CrossRefPubMed
19.
go back to reference Luo Y, Lee M, Kim HS et al (2016) Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer. Medicine 95:36CrossRef Luo Y, Lee M, Kim HS et al (2016) Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer. Medicine 95:36CrossRef
20.
go back to reference da Costa AA, Valadares CV, Baiocchi G et al (2015) Neoadjuvant chemotherapy followed by interval debulking surgery and the risk of platinum resistance in epithelial ovarian cancer. Ann Surg Oncol 22:971–978CrossRef da Costa AA, Valadares CV, Baiocchi G et al (2015) Neoadjuvant chemotherapy followed by interval debulking surgery and the risk of platinum resistance in epithelial ovarian cancer. Ann Surg Oncol 22:971–978CrossRef
21.
go back to reference Harter P, du Bois A, Hahmann M et al (2006) Surgery in recurrent ovarian cancer: the arbeitsgemeinschaft gynaekologische onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13(12):1702–1710CrossRefPubMed Harter P, du Bois A, Hahmann M et al (2006) Surgery in recurrent ovarian cancer: the arbeitsgemeinschaft gynaekologische onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13(12):1702–1710CrossRefPubMed
22.
go back to reference Harter P, Sehouli J, Reuss A et al (2011) Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the multicenter intergroup study DESKTOP II. A project of the AGO kommission OVAR, AGO study group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 21(2):289–295CrossRefPubMed Harter P, Sehouli J, Reuss A et al (2011) Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the multicenter intergroup study DESKTOP II. A project of the AGO kommission OVAR, AGO study group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 21(2):289–295CrossRefPubMed
23.
go back to reference Richardson DL, Mariani A, Cliby WA (2006) Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer. Gynecol Oncol 103(2):667–672CrossRefPubMed Richardson DL, Mariani A, Cliby WA (2006) Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer. Gynecol Oncol 103(2):667–672CrossRefPubMed
24.
go back to reference Peiretti M, Bristow RE, Zapardiel I, Gerardi M, Zanagnolo V, Biffi R, Landoni F, Bocciolone L, Aletti GD, Maggioni A (2012) Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecol Oncol 126(2):220–223CrossRefPubMed Peiretti M, Bristow RE, Zapardiel I, Gerardi M, Zanagnolo V, Biffi R, Landoni F, Bocciolone L, Aletti GD, Maggioni A (2012) Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecol Oncol 126(2):220–223CrossRefPubMed
25.
go back to reference Mourton SM, Temple LK, Abu-Rustum NR, Gemignani ML, Sonoda Y, Bochner BH, Barakat RR, Chi DS (2005) Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 99(3):608–614CrossRefPubMed Mourton SM, Temple LK, Abu-Rustum NR, Gemignani ML, Sonoda Y, Bochner BH, Barakat RR, Chi DS (2005) Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 99(3):608–614CrossRefPubMed
26.
go back to reference Fotopoulou C, Planchamp F, Aytulu T, Chiva L, Cina A, Ergönül O et al (2021) European society of gynaecological oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery. Int J Gynecol Cancer 31(9):1199–1206CrossRefPubMed Fotopoulou C, Planchamp F, Aytulu T, Chiva L, Cina A, Ergönül O et al (2021) European society of gynaecological oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery. Int J Gynecol Cancer 31(9):1199–1206CrossRefPubMed
27.
go back to reference Sier MF, van Gelder L, Ubbink DT, Bemelman WA, Oostenbroek RJ (2015) Factors affecting timing of closure and non-reversal of temporary ileostomies. Int J Color Dis 30(9):1185–1192CrossRef Sier MF, van Gelder L, Ubbink DT, Bemelman WA, Oostenbroek RJ (2015) Factors affecting timing of closure and non-reversal of temporary ileostomies. Int J Color Dis 30(9):1185–1192CrossRef
28.
go back to reference Waterland P, Goonetilleke K, Naumann DN, Sutcliff M, Soliman F (2015) Defunctioning ileostomy reversal rates and reasons for delayed reversal: does delay impact on complications of ileostomy reversal? A study of 170 defunctioning ileostomies. J Clin Med Res 7(9):685–689CrossRefPubMedPubMedCentral Waterland P, Goonetilleke K, Naumann DN, Sutcliff M, Soliman F (2015) Defunctioning ileostomy reversal rates and reasons for delayed reversal: does delay impact on complications of ileostomy reversal? A study of 170 defunctioning ileostomies. J Clin Med Res 7(9):685–689CrossRefPubMedPubMedCentral
29.
go back to reference Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W et al (2021) DESKTOP III Investigators. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. N Engl J Med 385(23):2123–2131CrossRefPubMed Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W et al (2021) DESKTOP III Investigators. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. N Engl J Med 385(23):2123–2131CrossRefPubMed
Metadata
Title
Comparison end-to-end anastomosis with ostomy after secondary surgical cytoreduction for recurrent high-grade serous ovarian cancer: observational single-center study
Authors
Luka Matak
Mislav Mikuš
Mario Ćorić
Giulia Spagnol
Magdalena Matak
Goran Vujić
Publication date
21-01-2023
Publisher
Springer Berlin Heidelberg
Published in
Archives of Gynecology and Obstetrics / Issue 1/2023
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-023-06918-9

Other articles of this Issue 1/2023

Archives of Gynecology and Obstetrics 1/2023 Go to the issue